Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Extension Study of Novartis Meningococcal B Recombinant Vaccine Booster or Catch‑up in Toddlers
2008-006301-17Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal group B vaccine in meningococcal meningitis, meningococcal disease, measles and 3 more, sponsored by Novartis. Primary endpoint: Sufficient immune response after fourth MenB booster dose. Started Jan 2009; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal meningitismeningococcal diseasemeaslesmumpsrubella
Beyond the preview
Go deeper on 2008-006301-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006301-17.